Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium (225Ac) alpitatug satetraxetan
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Administration
- Intravenous
01
Overview
Actinium (225Ac) alpitatug satetraxetan (JNJ-69086420) is a first-in-class, anti-human kallikrein-2 (hK2/KLK2) antibody-based targeted alpha therapy (radioligand therapy) developed by Johnson & Johnson (Janssen) for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). It consists of a humanized IgG1 monoclonal antibody (h11B6) targeting KLK2, conjugated via the satetraxetan chelator to the alpha-emitting radioisotope Actinium-225. Upon binding to KLK2-expressing prostate cancer cells, the conjugate delivers high-energy, short-range alpha radiation, inducing double-strand DNA breaks and tumor cell death while minimizing damage to surrounding healthy tissues.
- Other names
- 225Ac-DOTA-h11B6Alpi-satactinium Ac 225 alpitatug satetraxetanactinium Ac 225 alpitatug satretraxetecanactinium Ac-225 alpitatug satetraxetanactinium alpitatug satetraxetan Ac-225alpitatug satetraxetan
02
Targets
DNAHK2 (Hexokinase Type II)
Beyond the preview
Go deeper on actinium (225Ac) alpitatug satetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium (225Ac) alpitatug satetraxetan.